Other Cancers & Solid tumors: Archives News of the month
Low participation in cancer screening in India: a scoping review of breast and cervical cancer programs
Other Cancers & Solid tumors 8 min.
More than one-third of cancer cases in India are attributed to oral, breast, and cervical cancers [1, 2]. In India, breast and cervical cancers together account for nearly 39% of all cancers among women [3]. According to GLOBOCAN 2020 data, India reported an estimated 178,361 new cases and 90,408 deaths...
Prognostic model for early gastric cardia cancer after endoscopic submucosal dissection
Other Cancers & Solid tumors 8 min.
Early gastric cardia cancer is defined as cancerous lesions confined to the mucosa or submucosa, regardless of lymph node metastasis [1, 2]. Endoscopic submucosal dissection (ESD) has become a key treatment due to the minimal invasiveness and rapid recovery [3, 4]. However, some patients still experience...
OPTILATER: optimal long-term survival after cancer – a cross-sectional study protocol for a quantitative survey on the care situation of long-term cancer survivors in Germany
Other Cancers & Solid tumors 4 min.
The number of cancer survivors in Germany has been steadily increasing, due to advancements in treatment options and early detection [1]. In 2017 [2], there were 4.65 million cancer survivors, with approximately two-thirds being long-term survivors who have remained cancer-free for the last five years...
Timing and combinations of cardiovascular diseases in survivors of childhood, adolescent, and young adulthood cancer
Other Cancers & Solid tumors 6 min.
The treatment of cancer in children, adolescents, and young adults (CAYA) has advanced in recent decades, improving five-year survival rates to over 80% in many European and North American countries [1]. However, survivors may face various long-term complications, including severe or potentially life-threatening...
Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients
Other Cancers & Solid tumors 3 min.
Immunotherapy, especially PD-1/PD-L1 inhibitors, has been widely used in patients with non-small cell lung cancer (NSCLC). Single immunotherapy is mostly applied to patients with high PD-L1 expression. Immunotherapy combined with chemotherapy and antiangiogenic therapy is the standard of care for NSCLC...
